ISSCR News

ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility Treatment
Keith Alm Keith Alm

ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility Treatment

The ISSCR is aware of reports that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time. The safety risks associated with potential unintended genetic changes in embryos remain uncertain.

Read More
ISSCR Applauds FDA, FTC for Holding Deceptive Stem Cell Clinics Accountable
Keith Alm Keith Alm

ISSCR Applauds FDA, FTC for Holding Deceptive Stem Cell Clinics Accountable

The U.S. Food and Drug Administration has issued a warning letter to StemGenex of San Diego after an investigation found its cellular therapy does not conform with good manufacturing practice requirements, is being illegally marketed to treat conditions for which it has not been proven safe or effective, and is putting patients at risk…

Read More
ISSCR Voice is Heard on Capitol Hill
Keith Alm Keith Alm

ISSCR Voice is Heard on Capitol Hill

In mid-September, the U.S. Senate debated and passed a spending bill that included an increase in funding for the Department of Health and Human Services. The bill did not include a ban on federal funding for fetal tissue research, a measure the ISSCR opposed in a letter to leaders of the U.S. House and Senate, signed by 64 organizations.

Read More
ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research
Keith Alm Keith Alm

ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research

The ISSCR is troubled by the recent decision by the U.S. Department of Health and Human Services to “conduct a comprehensive review of all fetal tissue research.” The directive appears to come after intensive lobbying efforts by special interest groups with the goals of delaying or curtailing scientific research that relies on fetal tissue. Fetal tissue research has been necessary for the development of vaccines and therapies that have saved millions of lives, and continues to be important for the future of medicine. Decisions about how best to conduct research and to advance human health should be based on science and medicine, not ideology or politics.

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .